DATE CREATED: Jun28,2025
Number of Observations: 10
Number of Variables: 20

| **FileName** | **Variable\_label** | **Variable\_Name** | **Category** | **N\_\_Percent** | **Mean\_\_SD** | **Median\_Q1\_Q3** | **Range** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| lbalt | Blind\_id | Blind\_id |  | 8(100) |  |  |  |
| lbalt | Blinded\_SiteID | Blinded\_SiteID |  | 10(100) |  |  |  |
| lbalt | Visit Name | VISNAME | 1 Month Follow Up | 1(10) |  |  |  |
| lbalt | Visit Name | VISNAME | 6 Month Follow Up | 3(30) |  |  |  |
| lbalt | Visit Name | VISNAME | Baseline | 6(60) |  |  |  |
| lbalt | A1b. ALT Units | ALTUNT | (Empty string) | 1(10) |  |  |  |
| lbalt | A1b. ALT Units | ALTUNT | U/L | 9(90) |  |  |  |
| lbalt | A1c. ULN | ALTULN | 30 | 1(11.1) |  |  |  |
| lbalt | A1c. ULN | ALTULN | 40 | 1(11.1) |  |  |  |
| lbalt | A1c. ULN | ALTULN | 49 | 4(44.4) |  |  |  |
| lbalt | A1c. ULN | ALTULN | 55 | 1(11.1) |  |  |  |
| lbalt | A1c. ULN | ALTULN | 65 | 2(22.2) |  |  |  |
| lbalt | A1c. ULN | ALTULN | <NA> | 1(NA) |  |  |  |
| lbalt | A1d. Was the ALT result normal? | ALTNORM | (Empty string) | 1(10) |  |  |  |
| lbalt | A1d. Was the ALT result normal? | ALTNORM | No | 8(80) |  |  |  |
| lbalt | A1d. Was the ALT result normal? | ALTNORM | Yes | 1(10) |  |  |  |
| lbalt | A2. Did subject have any symptoms of liver disease? | ALTGISYM | No | 10(100) |  |  |  |
| lbalt | A3. Was INR measurement obtained? | INRYN | No | 1(10) |  |  |  |
| lbalt | A3. Was INR measurement obtained? | INRYN | Yes | 9(90) |  |  |  |
| lbalt | A3a. INR Result | INRRES | 0.9 | 1(11.1) |  |  |  |
| lbalt | A3a. INR Result | INRRES | 1 | 4(44.4) |  |  |  |
| lbalt | A3a. INR Result | INRRES | 1.1 | 3(33.3) |  |  |  |
| lbalt | A3a. INR Result | INRRES | 1.2 | 1(11.1) |  |  |  |
| lbalt | A3a. INR Result | INRRES | <NA> | 1(NA) |  |  |  |
| lbalt | A3b. ULN | INRULN | 1.1 | 4(50) |  |  |  |
| lbalt | A3b. ULN | INRULN | 1.2 | 2(25) |  |  |  |
| lbalt | A3b. ULN | INRULN | 2 | 1(12.5) |  |  |  |
| lbalt | A3b. ULN | INRULN | 9.9 | 1(12.5) |  |  |  |
| lbalt | A3b. ULN | INRULN | <NA> | 2(NA) |  |  |  |
| lbalt | A3c. Was the INR result normal? | INRNORMYN | (Empty string) | 1(10) |  |  |  |
| lbalt | A3c. Was the INR result normal? | INRNORMYN | No | 1(10) |  |  |  |
| lbalt | A3c. Was the INR result normal? | INRNORMYN | Yes | 8(80) |  |  |  |
| lbalt | A4. Was bilirubin measurement obtained? | BILIYN | No | 2(20) |  |  |  |
| lbalt | A4. Was bilirubin measurement obtained? | BILIYN | Yes | 8(80) |  |  |  |
| lbalt | A4a. Bilirubin Result | BILIRES | 0.3 | 2(25) |  |  |  |
| lbalt | A4a. Bilirubin Result | BILIRES | 0.4 | 2(25) |  |  |  |
| lbalt | A4a. Bilirubin Result | BILIRES | 0.6 | 2(25) |  |  |  |
| lbalt | A4a. Bilirubin Result | BILIRES | 0.7 | 2(25) |  |  |  |
| lbalt | A4a. Bilirubin Result | BILIRES | <NA> | 2(NA) |  |  |  |
| lbalt | A4b. Bilirubin Units | BILIUNT | (Empty string) | 2(20) |  |  |  |
| lbalt | A4b. Bilirubin Units | BILIUNT | mg/dL | 8(80) |  |  |  |
| lbalt | A4c. ULN | BILIULN | 0.6 | 1(12.5) |  |  |  |
| lbalt | A4c. ULN | BILIULN | 0.8 | 2(25) |  |  |  |
| lbalt | A4c. ULN | BILIULN | 1 | 2(25) |  |  |  |
| lbalt | A4c. ULN | BILIULN | 1.2 | 1(12.5) |  |  |  |
| lbalt | A4c. ULN | BILIULN | 1.4 | 1(12.5) |  |  |  |
| lbalt | A4c. ULN | BILIULN | 9.9 | 1(12.5) |  |  |  |
| lbalt | A4c. ULN | BILIULN | <NA> | 2(NA) |  |  |  |
| lbalt | A4d. Was the bilirubin result normal? | BILNORMYN | (Empty string) | 2(20) |  |  |  |
| lbalt | A4d. Was the bilirubin result normal? | BILNORMYN | No | 1(10) |  |  |  |
| lbalt | A4d. Was the bilirubin result normal? | BILNORMYN | Yes | 7(70) |  |  |  |
| lbalt | A5. Was an additional evaluation performed by the site's gastroenterologist /hepatologist? | ADDEVALYN | No | 5(50) |  |  |  |
| lbalt | A5. Was an additional evaluation performed by the site's gastroenterologist /hepatologist? | ADDEVALYN | Yes | 5(50) |  |  |  |
| lbalt | A5a. Please provide the results of the additional evaluation | ADDEVRES | (Empty string) | 5(50) |  |  |  |
| lbalt | A5a. Please provide the results of the additional evaluation | ADDEVRES | Additional labs drawn. GI evaluation scheduled | 1(10) |  |  |  |
| lbalt | A5a. Please provide the results of the additional evaluation | ADDEVRES | Liver US showed hepatic steatosis. Since liver enzymes decreasing, does not need to be seen in hepatology clinic at this time, can be managed by GI. Case discussed with hepatology provider an | 1(10) |  |  |  |
| lbalt | A5a. Please provide the results of the additional evaluation | ADDEVRES | New Labs Were Ordered Such As: Actin Ab Alpha-1-Antitrypsin Phenotype Ana Screen Cbc With Differential Ceruloplasmin Free T4 (Confirmation Only) Ggt Hepatic Function Panel (Incl Direct & Indi | 1(10) |  |  |  |
| lbalt | A5a. Please provide the results of the additional evaluation | ADDEVRES | No Additional Abnormal Results. Ultrasound Indicative Of Hepatic Steatosis. | 1(10) |  |  |  |
| lbalt | A5a. Please provide the results of the additional evaluation | ADDEVRES | Okay To Use Statin Drugs With Careful Monitoring Of Liver Function Tests. Follow Up With Gi In 3 Months To Get Hepatic Function Panel, Reinforce Recommendations To Exercise, Lose Weight And Eat Health | 1(10) |  |  |  |
| lbalt | A1. Age at Date of blood draw | ALTAge |  | 10(100) | 16.27(2.8) | 16.67(14.72,17.89) | 11.52,19.82 |
| lbalt | A1a. ALT Result | ALTRES |  | 9(90) | 135.44(93.2) | 123(52,171) | 36,301 |